-
公开(公告)号：EP1142574A1
公开(公告)日：2001-10-10
申请号：EP01201884.2
申请日：1998-02-10
申请人： SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES , Smithkline Beecham S.A. , SmithKline Beecham Corporation
发明人： Mention, Jacky A., SmithKline Beecham Lab. Pharma. , Sanroma Bordallo, J., SmithKl. Beecham S.A. Pharm. , Storm, Kevin, GlaxoSmithKline Pharmaceuticals
CPC分类号： A61K9/5084 , A61K9/0007 , A61K9/0095 , A61K9/2077 , A61K31/43 , A61K2300/00
摘要： Novel co-amoxiclav formulations are described comprising amoxycillin and potassium clavulanate in a ratio of 8:1, to provide a unit dosage of 1000/125mg.
摘要翻译： 描述了包含阿莫西林和克拉维酸钾的比例为8:1的新型共 - 阿莫克夫制剂，以提供1000 / 125mg的单位剂量。
-
公开(公告)号：EP1027433A1
公开(公告)日：2000-08-16
申请号：EP98932168.2
申请日：1998-06-09
申请人： SMITHKLINE BEECHAM PHARMA GmbH , SmithKline Beecham (Australia) Pty Ltd , SMITHKLINE BEECHAM PLC
发明人： LICHTENTHALER, Stefan,University of Heidelberg , BEYREUTHER, Konrad,University of Heidelberg , MASTERS, Colin, Louis , BROWN, Frank,SmithKline Beecham Pharmaceuticals , ALLSOP, David,SmithKline Beecham Pharmaceuticals
IPC分类号： C12N15/12 , C12N15/00 , C07K14/47 , A01K67/027 , C12N5/10
CPC分类号： C07K14/4711 , A01K2217/05
摘要： Constructs comprising a human APP or A4CT DNA sequence encoding mutations which lead to a higher ratio of βA41-42/βA41-40 than wild type and their use in the production of transgenic animals developing amyloid plaques as a model of Alzheimer's disease.
-
公开(公告)号：EP1027433B1
公开(公告)日：2003-09-03
申请号：EP98932168.2
申请日：1998-06-09
申请人： SmithKline Beecham Pharma GmbH & Co. KG , SmithKline Beecham (Australia) Pty Ltd , SMITHKLINE BEECHAM PLC
发明人： LICHTENTHALER, Stefan, University of Heidelberg , BEYREUTHER, Konrad, University of Heidelberg , MASTERS, Colin, Louis , BROWN, Frank, SmithKline Beecham Pharmaceuticals , ALLSOP, David, SmithKline Beecham Pharmaceuticals
IPC分类号： C12N15/12 , C12N15/00 , C07K14/47 , A01K67/027 , C12N5/10
CPC分类号： C07K14/4711 , A01K2217/05
摘要： Constructs comprising a human APP or A4CT DNA sequence encoding mutations which lead to a higher ratio of beta A41-42/ beta A41-40 than wild type and their use in the production of transgenic animals developing amyloid plaques as a model of Alzheimer's disease.
-
4.发明公开Pleuromutilin derivatives as antimicrobials 有权Pleuromutilin-Derivate als antimikrobielle Wirkstoffe
公开(公告)号：EP1930330A1
公开(公告)日：2008-06-11
申请号：EP08152170.0
申请日：1998-10-27
发明人： Berry, Valerie , Dabbs, Stephen , Frydrych, Colin, Henry , Hunt, Eric , Woodnutt, Gary , Sanderson, Francis, Dominic
IPC分类号： C07D453/02 , A61K31/435 , C07D451/02 , C07D471/08 , C07D487/08 , C07D211/62 , A61K31/445
CPC分类号： C07D451/02 , C07D211/20 , C07D211/54 , C07D451/04 , C07D453/02 , C07D471/04 , C07D487/04 , C07D487/08
摘要： Derivatives of pleuromutilin in which the glycolic ester moiety at position 14 is replaced by R 2 (CH 2 ) m X(CH 2 ) n CH 2 COO are of use in antimicrobial therapy. In which: each of n and m is independently 0, 1 or 2; X is selected from -O-, -S-, -S(O)-, -SO 2 -, -CO.O-, -NH-, -CONH-, -NHCONH- and a bond;R 1 is vinyl or ethyl;R 2 is a non-aromatic monocyclic or bicyclic group containing one or two basic nitrogen atoms and attached through a ring carbon atom; R 3 is H or OH; or the moiety R 2 (CH 2 ) m X(CH 2 ) n CH 2 COO at position 14 of (IA) or (IB) is replaced by R a R b C=CHCOO in which one of R a and R b is hydrogen and the other is R 2 or R a and R b together form R 2 ; or a pharmaceutically acceptable salt thereof
摘要翻译： 其中第14位的乙醇酸酯部分被R 2（CH 2）m X（CH 2）n CH 2 COO代替的去促胰岛素的衍生物在抗微生物治疗中是有用的。 其中：n和m各自独立地为0,1或2; X选自-O - ， - S - ， - S（O） - ， - SO 2 - ， - COO - ， - NH - ， - CONH - ， - NHCONH-和键; R 1是乙烯基或 乙基; R 2是含有一个或两个碱性氮原子并通过环碳原子连接的非芳族单环或双环基团; R 3是H或OH; 或（IA）或（IB）的第14位上的部分R 2（CH 2）m X（CH 2）n CH 2 COO被R a R b C = CHCOO代替，其中R a和R b之一为 氢，另一个是R 2或R a和R b一起形成R 2; 或其药学上可接受的盐
-
5.发明授权RECOMBINANT IL-5 ANTAGONISTS USEFUL IN TREATMENT OF IL-5 MEDIATED DISORDERS 失效重组IL-5拮抗剂，IL-5相关的疾病治疗
公开(公告)号：EP0800536B1
公开(公告)日：2006-11-29
申请号：EP95944692.3
申请日：1995-12-22
发明人： AMES, Robert S. , APPELBAUM, Edward Robert , CHAIKEN, Irwin M. , COOK, Richard M. , GROSS, Mitchell Stuart , HOLMES, Stephen Dudley , McMILLAN, Lynette Jane , THEISEN, Timothy Wayne
IPC分类号： C07K16/24 , C12N5/20 , C07K19/00 , C12N15/13 , A61K39/395 , A61P11/06 , A61P37/08 , A61P17/00 , C12N15/85 , G01N33/68
CPC分类号： C07K16/244 , A61K38/00 , A61K2039/505 , C07K14/5409 , C07K14/7155 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C12N2799/026 , G01N33/6869
-
6.发明公开Analysis and prediction of protein functional sub-types from protein sequence alignments 审中-公开分析和蛋白 - 官能亚型的预测来自蛋白质序列比对
公开(公告)号：EP1096411A3
公开(公告)日：2006-06-21
申请号：EP00203764.6
申请日：2000-10-27
IPC分类号： G06F19/00
摘要： Here we present a method for analysis and prediction of functional sub-types from multiple protein sequence alignments. Given an alignment and set of proteins grouped into sub-types according to some definition of function, such as enzymatic specificity, the method identifies positions that are indicative of functional differences by subtraction of sequence profiles, and analysis of positional entropy in the alignment.
-
公开(公告)号：EP0849361B1
公开(公告)日：2005-08-10
申请号：EP97310216.3
申请日：1997-12-17
申请人： SMITHKLINE BEECHAM CORPORATION , SmithKline Beecham plc , The Board of Regents, The University of Texas System
发明人： Bergsma, Derk J. , Brooks, David P. , Gellai, Miklos , Yanagisawa, Masashi , Wilson, Shelagh, c/o SmithKline Beecham Pharm.
IPC分类号： C12N15/12 , C07K14/47 , C07K16/28 , A61K39/395 , A61K38/17
CPC分类号： C07K14/575 , A61K38/00 , C07K16/26
-
公开(公告)号：EP0901459B1
公开(公告)日：2005-06-29
申请号：EP97917848.0
申请日：1997-04-04
发明人： VAN WAGENEN, Bradford, C. , DEL MAR, Eric, G. , SHEEHAN, Derek , BARMORE, Robert, M. , KEENAN, Richard, M. , KOTECHA, Nikesh, R. , THOMPSON, Mervyn , CALLAHAN, James, F.
IPC分类号： C07C217/34 , C07C217/14 , C07C217/28 , A61K31/135 , A61K31/44 , A61K31/395 , A61K31/38
CPC分类号： C07C311/29 , A61K31/137 , A61K31/18 , A61K31/277 , C07C217/30 , C07C217/60 , C07C217/62 , C07C255/46 , C07C255/54 , C07C323/25 , C07C2601/14 , C07C2603/74 , C07D213/65 , C07D317/58 , C07D333/70
摘要： The present invention features calcilytic compounds. 'Calcilytic compounds' refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
摘要翻译： 本发明具有钙化合物。 “钙化合物”是指能够抑制钙受体活性的化合物。 还描述了使用钙化合物抑制钙受体活性和/或在患者中获得有益效果; 以及可用于获得额外的钙化合物的技术。
-
公开(公告)号：EP1225884A4
公开(公告)日：2005-06-15
申请号：EP00975385
申请日：2000-10-26
IPC分类号： A61K47/32 , A61K20060101 , A61K9/20 , A61K9/28 , A61K31/19 , A61K31/277 , A61K31/44 , A61K31/74 , A61K45/00 , A61P11/00 , A61P11/06 , A61P25/28 , A61P29/00 , A61P35/00 , A61P43/00
CPC分类号： A61K9/2009 , A61K9/2027 , A61K31/19 , A61K31/44 , A61K31/74
-
公开(公告)号：EP0986389B1
公开(公告)日：2004-10-13
申请号：EP98925055.0
申请日：1998-05-29
IPC分类号： C07D211/22 , C07D211/78 , C07D211/76 , C07D405/12 , A61K31/445
CPC分类号： C07D405/12 , C07D211/22 , C07D211/74 , C07D211/78
摘要： Compounds of structure (1) are obtained by reduction of compounds of the structures (2a), (2b), (4a), (4b). Compounds of structure (1), especially where Z is a hydrogen atom or a 3,4-methylenedioxyphenyl group, are important intermediates for inter alia paroxetine.
摘要翻译： 结构（1）的化合物通过还原结构（2a），（2b），（4a），（4b）的化合物而获得。 结构（1）的化合物，尤其是其中Z是氢原子或3,4-亚甲二氧基苯基的化合物，尤其是帕罗西汀的重要中间体。
-
-
-
-
-
-
-
-
-
搜索结果
5474 条记录 (耗时 0.02 秒)
